VI International Symposium on Inflammatory Bowel DiseasesD. Rachmilewitz, R. Modigliani, D.K. Podolsky, D.B. Sachar, N. Tozun This book, the proceedings of Falk Symposium No. 123, VI International Symposium on Inflammatory Bowel Diseases, held in Istanbul, Turkey, on September 3-5, 2001, focuses on the issues and controversies pertinent to IBD in the 21st century. The achievements in medical, surgical, and in the basic sciences in the last twenty years since the first Jerusalem IBD Symposium are summarized in detail. Controversies with respect to the medical treatment of inflammatory bowel diseases are discussed. One section deals with surgical issues such as laparoscopic surgery in inflammatory bowel diseases, ileo-anal pouches and the surgical treatment of Crohn's disease. The last section is devoted to the biological treatment of IBD and to the needs both in medical science and in the clinic. |
Contents
Is the immunological response different in ulcerative colitis and Crohns disease? | 3 |
An update on lymphocyte activation and signal transduction in inflammation | 11 |
Are lessons from experimental models relevant for human inflammatory bowel disease? | 31 |
ANCAASCA differential diagnosis between ulcerative colitis and Crohns disease? | 39 |
Modalities to enhance restitution of mucosal injury | 47 |
Is the classification of Crohns disease of any real value? | 59 |
What can be done to prevent bone deterioration? | 64 |
Is the cancer risk different in ulcerative colitis and Crohns disease? | 70 |
Amelioration of experimental colitis by immunostimulatory DNA oligonucleotides | 125 |
AntiTNF therapy a fulfilment of great expectations | 133 |
Infliximab limited effects and troublesome sideeffects | 142 |
Thalidomide is it justified for usage in Crohns disease? | 149 |
Prevention of postoperative recurrence in Crohns disease standard of practice | 159 |
Postoperative maintenance medications are useful in patients with Crohns disease con | 163 |
When to resect and when to do strictureplasty for Crohns disease of the small intestine a review | 173 |
lleoanal pouches for inflammatory bowel disease state of the art 2001 | 188 |
Efficacy of budesonide in ulcerative colitis | 77 |
Budesonide who really needs it? | 81 |
Is metabolite monitoring essential for rational dosing of azathioprine and 6mercaptopurine? | 98 |
Immunosuppressors for inflammatory bowel disease how long is long enough? | 103 |
Crohns disease should be treated aggressively starting with immunomodulators | 111 |
Current recommendation for use of probiotics | 118 |
Laparoscopic colorectal surgery the case against | 194 |
Main achievements since the first Jerusalem IBD Symposium in September 1981 | 203 |
T lymphocyte apoptosis restoring mucosal immunological imbalance in Crohns disease by cytokinetargeted therapy | 211 |
Investing in the future of inflammatory bowel disease research if I had 10 million dollars how would I spend it? | 225 |
| 233 | |
Common terms and phrases
6-mercaptopurine active Crohn's disease ANCA antibiotics antibodies antigen apoptosis azathioprine bacterial bone budesonide CD4+ CDAI chronic Clin clinical Colon Rectum colorectal cancer compared controlled trial Crohn's disease cytokines decrease differentiation distal ulcerative colitis dose drug effects efficacy endoscopic enema epithelial cell expression fistulas FucT-VII function Gastroenterol Gastroenterology gene genetic growth factor healing hydrocortisone IFNy ileal immune response Immunol immunosuppressive increased induced inflammation inflammatory bowel disease infliximab inhibition interleukin intestinal epithelial kinase knockout laparoscopic laparoscopic surgery ligand lymphocytes lymphoma mechanisms mesalamine methotrexate mg/kg mice models molecules neutrophil oral P-selectin patients with Crohn's patients with ulcerative phenotype placebo postoperative pouch pouchitis prednisolone probiotic protein randomized receptor rectal recurrence regulation relapse remission resection risk role Rutgeerts segment selectin side-effects signalling small bowel STAT4 steroids strictureplasty strictures Surg surgery surgical Th1 cells thalidomide therapeutic therapy tion TPMT treated treatment of Crohn's ulcerative colitis weeks